

Development of lead compound for treatment of hearing loss caused by cisplatin

Kyungpook National University



NEUROSCIENCE	Hit
Product Type	Chemical Product
Indication	1st indication: Hearing Loss, Sensorineural (MeSH term)
Target	Serine/Threonine Kinase 17a (STK17A)
MoA(Mechanism of Action)	
Competitiveness	<p>First In Class</p> <ul style="list-style-type: none"> • The drug for ototoxic hearing loss caused by cisplatin that has been developed so far inhibits the anticancer effect. • Due to the nature of anticancer drug administration, research focusing on ‘treatment’ of side effects after the onset of cancer is needed rather than ‘prevention’ of side effects before onset of cancer.
Development Stage	Hit
Route of Administration	Parenteral-Intraperitoneal